Phase II study of UFT with leucovorin plus hepatic arterial infusion with irinotecan, 5-fluorouracil and leucovorin for non-resectable liver metastases of colorectal cancer

Chemotherapy

Volumn 55, Issue 2, 2009, Pages 76-82

  Idelevich, Efraim ^a   Greif, Franklin ^c   Mavor, Eli ^a   Miller, Rafael ^a   Kashtan, Hanoch ^a   Susmalian, Sergo ^a   Ariche, Arie ^b   Brenner, Baruch ^c   Baruch, Noa Ben ^a   Dinerman, Michael ^a   Shani, Adi ^a  

^a KAPLAN MEDICAL CENTER   (Israel)

^b Asharon Hospital   (Israel)

^c RABIN MEDICAL CENTER   (Israel)

Author keywords

5 Fluorouracil; Colorectal cancer; Hepatic arterial infusion; Irinotecan; Leucovorin; Liver metastases; Tegafur; UFT; Uracil

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; THYMIDYLATE SYNTHASE; UFT;

ADULT; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; HEPATIC ARTERY; HUMAN; HUMAN TISSUE; LIVER METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DIHYDROURACIL DEHYDROGENASE (NADP); FEMALE; FLUOROURACIL; HEPATIC ARTERY; HUMANS; INFUSIONS, INTRA-ARTERIAL; LEUCOVORIN; LIVER NEOPLASMS; MALE; MIDDLE AGED; TEGAFUR; URACIL;

EID: 57449121230     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000183732     Document Type: Article

References (43)

1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Libutti SK, Saltz LB, Rustgi AK, Tepper JE: Cancer of the colon; in De Vita VT, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology, ed 7. Philadelphia, Lippincott, 2005, pp 1061-1109.
3. Harmantas A, Rotstein LE, Langer B: Regional versus systemic chemotherapy in the treatment of colorectal carcinoma metastatic to the liver: is there a survival difference? Meta-analysis of the published literature. Cancer 1996;78:1639-1645.
4. Dizon DS, Kemeny NE: Intrahepatic arterial infusion of chemotherapy: clinical results. Semin Oncol 2002;29:126-135.
5. Kemeny N, Gonen M, Sullivan D, Schwartz L, Benedetti F, Saltz L, Stockman J, Fong Y, Jarnagin W, Bertino J, Tong W, Paty P: Phase I study of hepatic arterial infusion of floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer. J Clin Oncol 2001;19:2687-2695.
6. Kemeny N, Jarnagin W, Paty P, Gönen M, Schwartz L, Morse M, Leonard G, D'Angelica M, DeMatteo R, Blumgart L, Fong Y: Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. J Clin Oncol 2005;23:4888-4896.
7. Idelevich E, Man S, Lavrenkov K, Gluzman A, Geffen DB, Shani A: Irinotecan combined with bolus 5-fluorouracil and folinic acid for metastatic colorectal cancer: is this really a dangerous treatment? J Chemother 2004;16:487-490.
8. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:1041-1047.
9. Borner MM, Schöffski P, de Wit R, Caponigro F, Comella G, Sulkes A, Greim G, Peters GJ, van der Born K, Wanders J, de Boer RF, Martin C, Fumoleau P: Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer 2002;38:349-358.
10. Sadahiro S, Suzuki T, Maeda Y, Ishikawa K, Yasuda S, Makuuchi H, Murayama C: Phase I/II study of 24-hour infusion of irinotecan combined with oral UFT for metastatic colorectal cancer. Chemotherapy 2008;54:140-146.
11. Méndez M, Alfonso PG, Pujol E, González E, Castañon C, Cerezuela P, López-Mateos Y, Cruz JJ: Weekly irinotecan plus UFT and leucovorin as first-line chemotherapy of patients with advanced colorectal cancer. Invest New Drugs 2005;23:243-251.
12. Bajetta E, Di Bartolomeo M, Buzzoni R, Mariani L, Zilembo N, Ferrario E, Lo Vullo S, Aitini E, Isa L, Barone C, Jacobelli S, Recaldin E, Pinotti G, Iop A: Uracil/ftorafur/ leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study. Br J Cancer 2007;96:439-444.
13. Delord J-P, Bennouna J, Artru P, Perrier H, Husseini F, Desseigne F, François E, Faroux R, Smith D, Piedbois P, Naman H, Douillard JY, Bugat R: Phase II study of UFT with leucovorin and irinotecan (TEGAFIRI): first-line therapy for metastatic colorectal cancer Br J Cancer 2007;97:297-301.
14. Kusunoki M, Yanagi H, Noda M, Yoshikawa R, Yamamura T: Results of pharmacokinetic modulating chemotherapy in combination with hepatic arterial 5-fluorouracil infusion and oral UFT after resection of hepatic colorectal metastases. Cancer 2000;89:1228-1235.
15. Libra M, Navolanic PM, Talamini R, Cecchin E, Sartor F, Tumolo S, Masier S, Travali S, Boiocchi M, Toffoli G: Thymidylate synthetase mRNA levels are increased in liver metastases of colorectal cancer patients resistant to fluoropyrimidine-based chemotherapy. BMC Cancer 2004;4:11.
16. Wang TL, Diaz LA Jr, Romans K, Bardelli A, Saha S, Galizia G, Choti M, Donehower R, Parmigiani G, Shih IeM, Iacobuzio-Donahue C, Kinzler KW, Vogelstein B, Lengauer C, Velculescu VE: Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. Proc Natl Acad Sci USA 2004;101:3089-3094.
17. Fiorentini G, Lucchi SR, Giovanis P, Cantore M, Guadagni S, Papiani G: Irinotecan hepatic arterial infusion chemotherapy for hepatic metastases from colorectal cancer: results of a phase I clinical study. Tumori 2001;87:388-390.
18. van Riel JMGH, van Groeningen CJ, Kedde MA, Gall H, Leisink JMA, Gruia G, Pinedo HM, van der Vijgh WJ, Giaccone G: Continuous administration of irinotecan by hepatic arterial infusion: a phase I and pharmacokinetic study. Clin Cancer Res 2002;8:405-412.
19. van Riel JMGH, van Groeningen CJ, de Greve J, Gruia G, Pinedo HM, Giaccone G: Continuous infusion of hepatic arterial irinotecan in pretreated patients with colorectal cancer metastatic to the liver. Ann Oncol 2004;15:59-63.
20. Shimonov M, Hayat H, Chaitchik S, Brener J, Schachter P, Czerniak A: Combined systemic chronotherapy and hepatic artery infusion for the treatment of metastatic colorectal cancer confined to the liver. Chemotherapy 2005;51:111-115.
21. Tanaka K, Adam R, Giacchetti S, Castaing D, Kunstlinger F, Zidani R, Bismuth H, Jasmin C, Levi F: Intra-arterial hepatic infusion of circadian chronotherapy with irinotecan, 5-fluorouracil and oxaliplatin against liver metastases from colorectal cancer (abstract 2303). Proc Am Soc Clin Oncol 2002;21.
22. Guichard S, Terret C, Hennebelle I, Lochon I, Chevreau P, Frétigny E, Selves J, Chatelut E, Bugat R, Canal P: CPT-11 converting carboxylesterase and topoisomerase activities in tumour and normal colon and liver tissues. Br J Cancer 1999;80:364-370.
23. Fiorentini G, Rossi S, Bernardeschi P, Cantore M, Guadagni S: Is there a new drug beyond floxuridine for intra-arterial hepatic chemotherapy in liver metastases from colorectal cancer? J Clin Oncol 2005;23:2105.
24. Johnston PG, Fisher ER, Rockette HE, Fisher B, Wolmark N, Drake JC, Chabner BA, Allegra CJ: The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 1994;12:2640-2647.
25. Öhrling K, Edler D, Hallström M, Ragnhammar P, Blomgren H: Detection of thymidylate synthase expression in lymph node metastases of colorectal cancer can improve the prognostic information. J Clin Oncol 2005;23:5628-5634.
26. Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, Lenz HJ, Leichman CG, Leichman L, Diasio RB, Danenberg PV: Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 2000;6:1322-1327.
27. Ichikawa W, Uetake H, Shirota Y, Yamada H, Nishi N, Nihei Z, Sugihara K, Hirayama R: Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Clin Cancer Res 2003;9:786-791.
28. Tsuji T, Sawai T, Takeshita H, Nakagoe T, Hidaka S, Yamaguchi H, Yasutake T, Nagayasu T, Tagawa Y: Tumor dihydropyrimidine dehydrogenase expression is a useful marker in adjuvant therapy with oral fluoropyrimidines after curative resection of colorectal cancer. Cancer Chemother Pharmacol 2004;54:531-536.
29. Bismuth H, Adam R, Lévi F, Farabos C, Waechter F, Castaing D, Majno P, Engerran L: Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996;224:509-522.
30. Adam R, Huguet E, Azoulay D, Castaing D, Kunstlinger F, Levi F, Bismuth H: Hepatic resection after down-staging of unresectable hepatic colorectal metastases. Surg Oncol Clin N Am 2003;12:211-220.
31. Curley SA, Hohn DC, Roh MS: Hepatic artery infusion pumps: cannulation techniques and other surgical considerations. Langenbecks Arch Chir 1990;375:119-124.
32. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989;10:1-10.
33. Gehan EA: A generalized Wilcoxon test for comparing arbitrarily singly-censored samples. Biometrika 1965;52:202-223.
34. Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, de Gramont A: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229-237.
35. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
36. O'Connell MJ, Nagorney DM, Bernath AM, Schroeder G, Fitzgibbons RJ, Mailliard JA, Burch P, Bolton JS, Colon-Otero G, Krook JE: Sequential intrahepatic fluorodeoxyuridine and systemic fluorouracil plus leucovorin for the treatment of metastatic colorectal cancer confined to the liver. J Clin Oncol 1998;16:2528-2533.
37. Porta C, Danova M, Accurso S, Tinelli C, Girino M, Riccardi A, Palmeri S: Sequential intrahepatic and systemic fluoropyrimidine-based chemotherapy for metastatic colorectal cancer confined to the liver. A phase II study. Cancer Chemother Pharmacol 2001;47:423-428.
38. Rougier P, Ducreux M, Pignon JP, Elias D, Tigaud JM, Lumbroso J, Ruffie P, Lasser PH: Prognostic factors in patients with liver metastases from colorectal carcinoma treated with discontinuous intra-arterial hepatic chemotherapy. Eur J Cancer 1991;27:1226-1230.
39. Aschele C, Debernardis D, Casazza S, Antonelli G, Tunesi G, Baldo C, Lionetto R, Maley F, Sobrero A: Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracilbased chemotherapy. J Clin Oncol 1999;17:1760-1770.
40. Aschele C, Debernardis D, Tunesi G, Maley F, Sobrero A: Thymidylate synthase protein expression in primary colorectal cancer compared with the corresponding distant metastases and relationship with the clinical response to 5-fluorouracil. Clin Cancer Res 2000;6:4797-4802.
41. Johnston PG, Benson AB III, Catalano P, Rao MS, O'Dwyer PJ, Allegra CJ: Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites. J Clin Oncol 2003;21:815-819.
42. Gonen M, Hummer A, Zervoudakis A, Sullivan D, Fong Y, Banerjee D, Klimstra D, Cardon-Cardo C, Bertino J, Kemeny N: Thymidylate synthase expression in hepatic tumors is a predictor of survival and progression in patients with resectable metastatic colorectal cancer. J Clin Oncol 2003;21:406-412.
43. Saltz L, Danenberg K, Paty P, Kelsen D, Kemeny N, Salonga D, Park JM, Danenberg P: High thymidylate synthase (TS) expression does not preclude activity of CPT-11 in colorectal cancer (CRC) (abstract 1080). Proc Am Soc Clin Oncol 1998;17.